Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice
Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice
复制标题
DOI：
10.1186/s13244-020-00884-5
复制
发表时间：
2020-07-16
影响因子：
4.7
通讯作者：
Bilbao, Jose Ignacio
中科院分区：
文献类型：
--
作者：
Maas, Monique;Beets-Tan, Regina;Bilbao, Jose Ignacio
介入放射学在癌症治疗中发挥着越来越重要的作用。随访对于评估治疗成功率和检测局部和远处复发非常重要，需要提供随访建议。在ECIO 2018上，组织了一次ECIO-ESOI联合会议，以确定肝癌，肾癌和肺癌肿瘤干预的后续建议。治疗包括热消融、TACE和TARE。共评价了5个主题：结直肠癌肝转移（CRLM）消融、CRLM TARE、HCC TACE和TARE、肾癌消融和肺癌消融。评估的方式是FDG-PET-CT、CT、MRI和（对比增强）超声。在会议之前，选出了五名专家，进行了系统的审查，并提出了发言，所有小组成员在会议之前的电话会议上对发言进行了表决。这些声明在ECIO 2018的ECIO-ESOI会议上进行了介绍和讨论。本文件介绍了这些举措之后提出的建议。根据专家意见和现有证据，提出了肝癌、肾癌和肺癌的随访时间表。FDG-PET-CT、CT和MRI是推荐的检查方式，但应注意在干预后早期由于炎症引起的残留肿瘤或复发的假阳性体征。有必要进行前瞻性多中心研究，以验证新技术和新的反应标准。本文提出的建议，可用于临床实践中进行随访的肝癌，肺癌和肾癌患者接受介入局部治疗。
Interventional radiology plays an important and increasing role in cancer treatment. Follow-up is important to be able to assess treatment success and detect locoregional and distant recurrence and recommendations for follow-up are needed. At ECIO 2018, a joint ECIO-ESOI session was organized to establish follow-up recommendations for oncologic intervention in liver, renal, and lung cancer. Treatments included thermal ablation, TACE, and TARE. In total five topics were evaluated: ablation in colorectal liver metastases (CRLM), TARE in CRLM, TACE and TARE in HCC, ablation in renal cancer, and ablation in lung cancer. Evaluated modalities were FDG-PET-CT, CT, MRI, and (contrast-enhanced) ultrasound. Prior to the session, five experts were selected and performed a systematic review and presented statements, which were voted on in a telephone conference prior to the meeting by all panelists. These statements were presented and discussed at the ECIO-ESOI session at ECIO 2018. This paper presents the recommendations that followed from these initiatives. Based on expert opinions and the available evidence, follow-up schedules were proposed for liver cancer, renal cancer, and lung cancer. FDG-PET-CT, CT, and MRI are the recommended modalities, but one should beware of false-positive signs of residual tumor or recurrence due to inflammation early after the intervention. There is a need for prospective preferably multicenter studies to validate new techniques and new response criteria. This paper presents recommendations that can be used in clinical practice to perform the follow-up of patients with liver, lung, and renal cancer who were treated with interventional locoregional therapies.